Share this article on:

Editorial introductions

Section Editor(s): Broxmeyer, Hal E.; Melnick, Ari M.

Current Opinion in Hematology: July 2014 - Volume 21 - Issue 4 - p v–vi
doi: 10.1097/MOH.0000000000000065
Editorial introductions

Current Opinion in Hematology was launched in 1994. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of hematology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.

Back to Top | Article Outline


Hal E. Broxmeyer

Dr Hal E. Broxmeyer is Distinguished Professor, Professor of Microbiology and Immunology, Mary Margaret Walther Professor Emeritus, and Co-Leader Program on Hematopoiesis, Leukemia, and Immunology, Indiana University Simon Cancer Center, USA, and former Chairman of Microbiology and Immunology and Scientific Director, Walther Oncology Center, at the Indiana University School of Medicine, Indianapolis, IN, USA. He received a BS degree, Brooklyn College, City University of New York, USA, in 1966, an MS degree from Long Island University, Brooklyn Center, USA in 1969 and a PhD from New York University, USA, in 1973. He did post-doctoral training in 1973–1975 at Kingston General Hospital, Queens University Kingston, Ontario, Canada. From 1975–1983 he worked at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, USA, rising from the ranks of Associate Researcher to that of Associate Member. He was also Assistant Professor of Biology, Sloan Kettering Division of Cornell University Graduate School of Medical Sciences, New York, USA, before being recruited to the Indiana University School of Medicine in 1983 as an Associate Professor of Medicine. To date, he has published 729 scientific papers (505 refereed papers and 224 Reviews/Book Chapters). Broxmeyer's laboratory studies mechanisms regulating hematopoietic stem and progenitor cell, embryonic stem cell and induced pluripotent stem cell: proliferation, self-renewal, survival, differentiation and migration (homing/mobilization). He was involved in establishing the field of cord blood transplantation. His publications have been cited 35,844 times and the H-Factor for publications is 98.

Dr Broxmeyer's Awards include: New York University Founders Day Award (1973); Mellor Award (2nd prize 1976; 1st prize 1977) and Boyer Award (1983) from MSKCC; Special Fellow (1976–1978) and Scholar Award (1978–1983) from the Leukemia Lymphoma Society; Merit Award, National Cancer Institute (1987–1995); Variety Club Award (1992 and 1993), Indiana; Gold Medal of City of Paris (1993); World of Difference Award, Indiana Health Industry Forum (1997); Who's Who in Health Care, Indianapolis Business Journal (IBJ) (2002); Health Care Heroes Award, IBJ (2002); Karl Landsteiner Award, American Association of Blood Banks (2002); Prestigious External Award Recognition, IUPUI (2003); Distinguished Alumni Award, Long Island University (2005); Joseph T. Taylor Excellence in Diversity Award, Indiana University (2006); Dirk van Bekkum Award, Autologous Blood and Bone Marrow Society (2006); E. Donnall Thomas Prize and Lecture, American Society of Hematology (2007); Glenn W. Irwin Jr. M.D., Distinguished Faculty Award, Indiana University School of Medicine Alumni Association (2008); State of Indiana General Assembly House Resolution No. 46 (2008); Mission Advancement Award, Leukemia Lymphoma Society (2008); Cord Blood Pioneering Award, Int. Cord Blood Symposium (2008); Till and McCullough Award, Canadian Bone Marrow Transplant Group (2010); Donald Metcalf Award, Int. Soc. Expt. Hematol. (2011); and Elected Fellow of the American Association for the Advancement of Science (AAAS) (2013).

Dr Broxmeyer is a Past President of the American Society of Hematology (ASH; 2010), past President of the International Society for Experimental Hematology (ISEH, 1990, 1991), past Chairman, and member, Board of Scientific Councilors, National Space Biomedical Research Institute (NSBRI/NASA, 1998–2006), and Chairman Emeritus, Board of Directors, National Disease Research Interchange, Philadelphia, PA.

Back to Top | Article Outline

Ari M. Melnick

Dr Melnick is the Gebroe Family Professor of Hematology/Oncology at Weill Cornell Medical College (WCMC), New York, USA (holding this role since 2013), Director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences, New York, USA, Director of the Internal Medicine Research Residency and Director of the WCMC Epigenomics Core Facility.

He completed his medical degree at the University of Buenos Aries, Argentina, in 1990 and continued his clinical training with residencies in internal medicine and subsequently, hematology and oncology at Mount Sinai Medical Center, New York, USA. Following this, he completed post-doctoral fellowships in transcriptional regulation in leukemias with Dr Jonathan Licht at Mount Sinai Medical Center and transcriptional regulation of chromatin with Dr Leonard Freedman at Memorial Sloan-Kettering Cancer Center, USA.

Dr Melnick started his own lab in 2002 and has published over 125 papers. His research interests are focused on transcriptional and epigenetic regulation in hematology malignancies, which has led to the development of novel therapies to correct aberrant transcriptional regulation by his group. He has received a number of awards for his work including the Leukemia and Lymphoma Society Scholar Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research.

In addition to this, Dr Melnick was the director of the Mount Sinai School of Medicine fellowship program and the Weill Cornell Research Track Residency Program, where he was able to pursue his interest in mentoring trainees and helping to widen career development and training programs for junior scientists.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins